Human GIP Protein
Catalog No: GIP-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
- Activity
- Activity verified
Product overview
Recombinant Human GIP Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Glu22-Gln93 (UniProt accession: P09681).
Product Details
- Molecular Aliases
- GIP; Incretin
- Protein Length
- Glu22-Gln93
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 34.9 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human GIP on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human GIP is greater than 95% as determined by SEC-HPLC.
Immobilized Human GIP, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-GIP Antibody, hFc Tag with the EC50 of 58.2ng/ml determined by ELISA.
Background
The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.
References
- Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020 Mar;125:170202. doi: 10.1016/j.peptides.2019.170202. Epub 2019 Nov 19. PMID: 31756366.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.